ESR1 and breast cancer: Approximately eighty percent of all ER+ breast cancers are also positive for PR and while selective ER modulators (SERMs) are routinely used as adjuvant therapy in women with PR+ breast cancers, relatively limited progress has been made in the development of effective PR-targeting therapies in the clinic.